Mather Group LLC. Buys 37,037 Shares of Kenvue Inc. $KVUE

Mather Group LLC. boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 122.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 67,206 shares of the company’s stock after buying an additional 37,037 shares during the quarter. Mather Group LLC.’s holdings in Kenvue were worth $1,159,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of KVUE. Salomon & Ludwin LLC bought a new stake in shares of Kenvue in the 3rd quarter worth about $25,000. NBT Bank N A NY grew its holdings in Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after purchasing an additional 1,006 shares during the last quarter. Cornerstone Planning Group LLC raised its position in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares during the period. Golden State Wealth Management LLC lifted its stake in Kenvue by 150.1% in the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after purchasing an additional 1,190 shares during the last quarter. Finally, Trust Co. of Vermont lifted its stake in Kenvue by 50.9% in the third quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock worth $39,000 after purchasing an additional 804 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE:KVUE opened at $17.52 on Friday. The firm’s 50 day simple moving average is $18.01 and its 200-day simple moving average is $17.14. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The firm has a market cap of $33.57 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 3.99 and a beta of 0.51.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. The firm had revenue of $3.78 billion during the quarter, compared to analyst estimates of $3.68 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.Kenvue’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.26 earnings per share. As a group, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were given a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. Kenvue’s dividend payout ratio is presently 107.79%.

Analyst Ratings Changes

KVUE has been the topic of a number of analyst reports. Barclays upped their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Friday, March 6th. UBS Group raised their price target on Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Citigroup upped their price objective on Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, February 18th. Finally, Canaccord Genuity Group increased their target price on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.